Viewing Study NCT05118334


Ignite Creation Date: 2025-12-25 @ 2:20 AM
Ignite Modification Date: 2026-01-07 @ 7:00 AM
Study NCT ID: NCT05118334
Status: COMPLETED
Last Update Posted: 2023-02-23
First Post: 2021-11-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module